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Abstract
Positive-strand RNA virus infections can induce the stress-related unfolded protein
response (UPR) in host cells. This study found that enterovirus A71 (EVA71) utilizes host
UDP-glucose glycoprotein glucosyltransferase 1 (UGGT1), a key endoplasmic reticulum
protein (ER) involved in UPR, to enhance viral replication and virulence. EVA71 forms repli-
cation complexes (RCs) on cellular membranes that contain a mix of host and viral proteins
to facilitate viral replication, but the components and processes involved in the assembly
and function of RCs are not fully understood. Using EVA71 as a model, this study found that
host UGGT1 and viral 3D polymerase co-precipitate along with other factors on membra-
nous replication complexes to enhance viral replication. Increased UGGT1 levels elevated
viral growth rates, while viral pathogenicity was observed to be lower in heterozygous knock-
out mice (Uggt1 +/- mice). These findings provide important insight on the role of UPR and
host UGGT1 in regulating RNA virus replication and pathogenicity.
Author summary
Positive-strand RNA viruses are adept at hijacking host cell machinery to promote viral
propagation, including the formation of RCs containing viral and host proteins on intra-
cellular membranes to facilitate virion assembly and avoid detection by host defense
mechanisms. However, the processes by which RCs are assembled, as well as the host pro-
teins involved, have not been fully elucidated as yet. Here, we show that the endoplasmic
reticulum (ER) protein UGGT1, a key regulator of the UPR host defense mechanism, co-
precipitates with the 3D polymerase of EVA71 to facilitate RC formation, enhance viral
RNA synthesis, and promote viral replication. Knockout of Uggt1 reduced viral pathoge-
nicity in animal studies. These findings highlight the role to which viruses can hijack key
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host proteins to promote viral replication, and may serve as the basis for the development
of novel anti-viral strategies.
Introduction
Positive-strand RNA viruses are capable of infecting a wide range of hosts, ranging from algae
to humans. The mechanism underlying this broad range of pathogenicity spanning different
hosts and tissue types involves the use of cellular membranes for viral genomic RNA replica-
tion, which provides a number of key benefits. Membrane structures allow buildup of a high
local concentration of viral proteins, while also serving as a protective screen against protease
cleavage. Membranes can further provide a structural scaffold that facilitates the correct spatial
organization of viral replication complex (RC) components, and RCs can also be protected by
the membrane against host infection sensors or other defense mechanisms [1,2]. Different pos-
itive-strand RNA viruses utilize different cellular membranes, resulting in a variety of morpho-
logical alterations; however, the sequences and functional domains of key viral proteins
involved in membrane utilization are quite conserved among these viruses, suggesting that
there are common strategies for the incorporation of cellular membranes into viral RCs [3,4].
Picornaviruses are a family of small positive-strand RNA viruses that include several notori-
ous animal and human pathogens, such as rhinoviruses, Coxsackie viruses, foot and mouth
disease virus, hepatitis A virus, and enterovirus A71 (EVA71). EVA71 typically causes hand,
foot, and mouth disease (HFMD), which is generally regarded as a mild childhood illness [5];
however, not along after its initial isolation in California during 1969 [6], several deadly
EVA71 epidemics occurred in the 1970s [7–9], and the virus has recently been associated with
severe neurological complications, such as brain stem encephalitis and acute flaccid paralysis,
in Asian infants and young children [10]. Several large HFMD outbreaks in the Asia-Pacific
region have also occurred in recent years, including Malaysia, 2007 [11]; Taiwan, 1998 [12];
Singapore, 2000 [13]; Japan, 1997 and 2000 [14]; Shandong, China, 2007 [15]; and Fuyang,
China, 2008 [16,17].
EVA71 genomic RNA is about 7,400 nucleotides (nt) long, and upon viral entry into host
cells, the RNA genome is directly translated into one polyprotein, which is then cleaved by
virus-specific proteases into structural and replication proteins. About 10 mature proteins and
several other intermediate products are generated during this process, and these elements go
on to perform many independent functions in the viral life cycle [18,19]. One non-structural
protein that plays a key role in EVA71 replication is the 3D viral polymerase, which is encoded
in the P3 viral genome region and is cleaved by viral proteases from the 3CD precursor pro-
teinase after translation [20–22]. The 3D polymerase is an RNA-dependent RNA polymerase
(RdRp) responsible for plus-strand and minus-strand viral RNA synthesis in viral RCs [23,24].
The first step in this process involves uridylylation of the small viral protein, VPg, in which
two uridine monophosphate (UMP) molecules bind to the hydroxyl group of a tyrosine resi-
due near the N-terminus of VPg via a reaction catalyzed by the viral 3D polymerase [25]. The
3D polymerase can also facilitate viral RNA chain elongation in viral RCs [26–29], and is
known to interact with several host proteins, including Sam68 [30].
During picornavirus infection, viral RNA replication occurs on the cytoplasmic surfaces of
single-membrane vesicles derived from the endoplasmic reticulum (ER), and the membranes
can serve to accelerate RC assembly during positive-strand genomic RNA replication [31].
Viral proteins 2BC and 3A are known to be involved in viral RC formation, and these proteins
contain hydrophobic domains that allow them to interact extensively with cellular membranes
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[32,33]. Viral protein 3A also plays an important role in membrane reorganization through its
interactions with cellular proteins such as GBF1, Arf1, and PI4KIIIβ [34–37]. Other non-struc-
tural viral proteins are known to interfere with cellular membrane metabolism, and even rear-
range subcellular organelles. Many viral and host proteins and lipids are involved in the
membrane remodeling process induced by RCs, and the underlying mechanisms are complex
and not well understood; for example, the 3D viral polymerase does not have obvious mem-
brane binding sequences or properties, and its presence in RCs is therefore quite puzzling.
To enhance the current understanding of RC components and viral RNA replication fol-
lowing picornavirus infection, we used EVA71 as a model to evaluate interactions between the
3D viral polymerase and host proteins after virus infection. Proteins associated with 3D poly-
merase were immunoprecipitated with an anti-3D monoclonal antibody, and results showed
that the host protein, UDP-glucose glycoprotein glucosyltransferase 1 (UGGT1), associates
with 3D polymerase. UGGT1, also known as HUGT1, is a soluble ER protein that selectively
reglucosylates unfolded glycoproteins, thus providing quality control for proteins transported
out of the ER. Viral infections drive the accumulation of unfolded and misfolded proteins in
the ER [38], and to reduce the adverse effects of such accumulation, the host cell utilizes a
stress-related defense mechanism known as the unfolded protein response (UPR) to decrease
the load of newly synthesized proteins within the ER and eliminate incorrectly folded proteins
[39–41]. Alternatively, proteins possessing non-native structures are recognized by UGGT1,
reglucosylated, and targeted for chaperone rebinding and ER retention [42]. UGGT1 can also
add glucose molecules to the N-linked glycans of non-glucosylated substrates that fail quality
control tests, thereby supporting additional rounds of chaperone binding and ER retention
[42–46]. It has been shown that the disruption of protein folding in the ER induces UGGT1
expression [47]. Importantly, during EVA71 infection, we found that UGGT1 expression levels
increase, and UGGT1 also redeploys from the ER to the cytoplasm, where it acts as a positive
regulator of viral RNA synthesis. The 3A viral protein was also shown to increase UGGT1 and
3D polymerase levels in the membrane fraction. We further observed that the pathogenicity of
EVA71 infection decreased in heterozygous Uggt1 knockout mice. These findings shed light
on the molecular processes driven by host UGGT1 and viral 3D protein association, and pro-
vide important insight on the relationship between virus pathogenicity and viral-host
interactions.
Results
UGGT1 co-precipitates with viral 3D polymerase during EVA71 infection
To better understand how the EVA71 3D polymerase associates with host proteins and other
components of the viral replication machinery at RCs, we sought to identify novel host factors
that associate with the 3D polymerase in RCs. Accordingly, an anti-3D monoclonal antibody
was used to perform immunoprecipitation assays, in order to purify proteins associating with
the 3D polymerase in infected cells. We immunoprecipitated mock-infected and EVA71-in-
fected cell lysates with this anti-3D monoclonal antibody, and subsequently identified seven
major protein bands that appeared in the EVA71-infected lysates, but not in the mock-infected
lysates (Fig 1A). We excised the protein bands that specifically associated with the 3D polymer-
ase as shown in Fig 1A, digested the excisions with trypsin, and subjected them to matrix-assis-
ted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) analysis.
Table 1 presents these seven proteins and their accession numbers, as obtained from the US
National Center for Biotechnology Information (NCBI) protein database (Table 1). The seven
proteins included one viral protein, the EVA71 3CD polyprotein (Fig 1A, band 5), and six host
proteins: UGGT1, elongation factor 2, interleukin enhancer binding factor 3 (ILF3), lamina-
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Fig 1. Co-precipitation of UGGT1 and the EVA71 3D viral polymerase. (A) At 6 hours post-infection, lysates from EVA71-infected or
mock-infected cells were immunoprecipitated with anti-3D monoclonal antibody, and the precipitates were separated using SDS-PAGE,
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associated polypeptide 2 isoform alpha, T-complex protein 1 subunit theta, and eukaryotic
translation initiation factor 3. The identified peptide sequences accounted for 24% of the
UGGT1 sequence (Table 1 and S1 Fig). The ER protein, UGGT1 (Fig 1A, band 1), was selected
for further investigation. We performed Western blot analysis to confirm that UGGT1 associ-
ated with the 3D polymerase following EVA71 infection. Co-IP experiments using EVA71-in-
fected or mock-infected RD cell extracts were conducted, and the anti-3D antibody was able to
immunoprecipitate UGGT1 (Fig 1B, lanes 3 and 4), while reciprocal co-IP experiments
showed that the anti-UGGT1 antibody was also able to immunoprecipitate 3D polymerase in
EVA71-infected cell lysates (Fig 1B, lanes 7 and 8). Viral capsid proteins were not observed in
the UGGT1-viral protein complexes (Fig 1B). These results provide evidence that UGGT1
interacts with the EVA71 viral 3D polymerase.
EVA71 infection increases UGGT1 levels and interaction with 3D
polymerase at RCs
Host cells can mobilize the UPR in an attempt to restrict viral infection, and UGGT1 is known
to be a key UPR factor in the ER. To ascertain UGGT1 expression levels in EVA71-infected
cells, we compared UGGT1 levels in mock-infected and infected cells. UGGT1 expression lev-
els were found to increase upon viral infection (Fig 1B and 1C, input lysate). It is known that
the 3D viral polymerase associates with viral RNA, and to determine whether UGGT1 interac-
tion with 3D polymerase was mediated by RNA, we examined the interaction between
UGGT1 and viral genomic RNA. Treatment with RNase A prior to co-IP assays did not reduce
UGGT1 interaction with the EVA71 3D polymerase, indicating that this interaction was not
mediated by viral genomic RNA (Fig 1C, lanes 5 and 6). Host protein ILF3 is an RNA-binding
after which silver staining was applied for visualization. The seven labeled bands were excised, digested with trypsin, and analyzed by
MALDI-TOF MS. (B) EVA71-infected and mock-infected cells were harvested and subjected to co-IP assays with anti-3D antibody (lanes 3
and 4) or mouse IgG (lanes 5 and 6); or anti-UGGT1 antibody (lanes 7 and 8) or rabbit IgG (lanes 9 and 10). The precipitates were analyzed
using Western blotting with anti-UGGT1, anti-3D, anti-VP2, and anti-actin antibodies. (C) Cells were harvested at 6 h post-transfection, and
lysates were treated with RNase A prior to being used in co-IP assays with an anti-3D antibody. Actin served as a loading control.
Degradation of RNA was confirmed by RNA gel analysis. The precipitates were analyzed using Western blotting with anti-UGGT1, anti-
ILF3, and anti-actin antibodies. (D) Membrane protein fractions were purified from EVA71-infected and mock-infected cells, and
immunoprecipitation results with anti-3D antibody were analyzed by Western blotting with anti-3D, anti-3A, anti-VP2, and anti-UGGT1
antibodies. Expression of UGGT1, 3D, 3CD, 3AB, and 3A in the input lysate are shown. (E) EVA71-infected and mock-infected cells were
fixed and stained with anti-UGGT1 and anti-3D antibodies at 6 h post-infection. An anti-UGGT1 antibody was used in panels 1 and 5, which
were examined using a FITC filter. An anti-3D antibody was used in panels 2 and 6, which were examined using a rhodamine filter. Panels 3
and 7 display Hoechst 33258 staining results, and were examined using a 4’,6-diamidino-2-phenylindole (DAPI) filter. Panels 4 and 8
display merged rhodamine, FITC, and DAPI images. (F) EVA71-infected or mock-infected cells were fixed and stained with antibodies
against UGGT1 and double strand RNA. Results with the anti-double strand RNA antibody are shown in panels 1 and 5, which were
examined using a rhodamine filter. Anti-UGGT1 antibody was used for panels 2 and 6, which were examined using an FITC filter. Panels 3
and 7 display Hoechst 33258 staining results, which were examined using a DAPI filter. Panels 4 and 8 display merged rhodamine, FITC,
and DAPI images.
https://doi.org/10.1371/journal.ppat.1006375.g001
Table 1. MALDI-TOF results of proteins associating with the EVA71 3D polymerase.
Spot No. Protein Name Match NCBI GI No. Protein Score Sequence Coverage Mass (Da)
1 UDP-glucose glycoprotein glucosyltransferase 1 GI: 9910280 122 24% 177819
2 Elongation factor 2 GI: 4503483 185 46% 96246
3 Interleukin enhancer binding factor 3 GI: 212549553 88 47% 92144
4 Lamina-associated polypeptide 2, isoform alpha GI: 1174689 70 39% 76016
5 Enterovirus 71 3CD GI: 126567368 128 42% 73167
6 T-complex protein 1 subunit theta GI: 48762932 88 51% 60153
7 Eukaryotic translation initiation factor 3 GI: 4503513 86 55% 36878
https://doi.org/10.1371/journal.ppat.1006375.t001
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protein that associates with the 3D viral polymerase (Table 1). Here, ILF3 served as a positive
control for RNase A treatment. ILF3 association with the 3D viral polymerase was reduced
after RNase A was applied prior to co-IP assays. Degradation of RNA was confirmed by RNA
gel analysis (Fig 1C). To clarify the components of the UGGT1-3D complex, we purified the
membrane fraction of EVA71-infected cells, and performed an immunoprecipitation assay to
identify other viral proteins involved. The results shown in Fig 1D indicate that the 3A viral
protein was also present in the UGGT1-3D complex, and this provides evidence to support an
indirect interaction dependent on other viral proteins between UGGT1 and the 3D polymer-
ase. In addition, as the 3D viral polymerase is located in the nucleus and cytoplasm at different
stages of viral replication, while UGGT1 is located predominantly in the ER, we therefore
sought to examine how UGGT1 and the 3D polymerase colocalize intracellularly during
EVA71 infection, using fluorescence confocal microscopy. In mock-infected cells, UGGT1
was predominantly localized in the cytoplasm (Fig 1E, panel 4), while in EVA71-infected cells,
both the 3D polymerase and UGGT1 were localized in the cytoplasm at 6 h post-infection (Fig
1E, panel 8). Moreover, when an anti-dsRNA antibody was used to highlight the location of
RCs in an immunofluorescence assay, staining results showed that UGGT1 associates with
RCs in the cytoplasm (Fig 1F). However, co-IP experiments conducted in uninfected cells co-
expressing Flag-UGGT1 and HA-3D showed that anti-HA antibodies did not precipitate Flag-
UGGT1, nor did anti-Flag antibodies precipitate HA-3D. Anti-HA antibodies also did not co-
immunoprecipitate endogenous UGGT1 from RD cells expressing HA-3D (Fig 2). These
results show that UGGT1 can co-precipitate with EVA71 viral polymerases in RCs, and further
indicate that viral infection is essential for UGGT1 co-purification with the EVA71 3D poly-
merase. Together, these findings confirm that upon viral infection, UGGT1 levels increase,
and UGGT1 co-precipitates with 3D polymerase and other factors on membranous replication
complexes.
UGGT1 is a positive regulator of viral replication and propagation
To ascertain the effect of UGGT1 on viral replication and propagation, we infected (negative
control) NC or UGGT1 siRNA-transfected cells with a high titer of EVA71 (MOI = 10), and
assessed 3D polymerase expression at 6 h post-infection by confocal microscopy. We first ana-
lyzed the effect of UGGT1 knockdown on siRNA-transfected cell viability. Cell viability was
measured by a CellTiter-Glo Luminescent Cell Viability kit (Promega), which quantitates the
ATP generated in viable cells. The results presented in S2 Fig demonstrate that cell prolifera-
tion and viability were not significantly different between NC siRNA- and UGGT1 siRNA-
transfected cells (S2 Fig). In UGGT1 siRNA-treated cells, viral protein expression was signifi-
cantly lower compared to NC siRNA-treated cells (Fig 3A, panels 10 and 14). These results
suggest that UGGT1 plays a critical role in enhancing viral replication. To further evaluate the
effects of UGGT1 on EVA71 replication rates, we treated RD cells with NC or UGGT1 siRNA,
and then infected these cells with a high (MOI = 10) or low (MOI = 0.1) EVA71 titer. The pla-
que assay was used to detect viral yields at various timepoints post-infection. Viral replication
rates were found to be lower in uggt1 knockdown cells as compared to NC siRNA-treated cells,
regardless of MOI levels (Fig 3B and 3C). These results support the hypothesis that UGGT1 is
a positive regulator during EVA71 infection. We repeated this experiment in SF268 glioblas-
toma (SF268) cells to determine whether the effects of UGGT1 on viral replication are specific
to a given cell type. Results showed that viral replication rates were also lower in UGGT1
siRNA-treated SF268 cells, as compared to NC siRNA-treated cells (S3A and S3B Fig). To
avoid siRNA off-target effects, we used EVA71 to infect cells overexpressing UGGT1, and sub-
sequently measured virus yields at 4, 6, and 8 h post-infection. The results showed that viral
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replication increased when UGGT1 was overexpressed in infected cells (Fig 3D, S3C and S3D
Fig).
We further evaluated the role of UGGT1 in enterovirus D68 (EVD68). EVD68 is classified
in a different group as other more common enteroviruses, such as EVA71 and coxsackievirus
A16, but this does not mean it is less pathogenic: in a 2014 outbreak of EVD68, a total of 1,152
people in United States were confirmed as having acute respiratory infections caused by
EVD68. It is important for emergency clinicians to recognize this viral illness, because it can
lead to respiratory distress that requires hospitalization or, in some instances, intensive care
[48]. After infecting NC or UGGT1 siRNA-treated cells with EVD68, we evaluated viral repli-
cation rates, and observed that EVD68 viral titers were lower in UGGT1 siRNA-transfected
cells as compared to NC siRNA-transfected cells (S3E and S3F Fig). These results confirm that
UGGT1 is a positive regulator of EVA71 and EVD68 replication, and suggest that it may be a
commonly utilized host factor for viral replication in enteroviruses.
Fig 2. In vivo interaction between 3D polymerase and UGGT1. Uninfected RD cells were co-transfected
with pFLAG-UGGT1 or pHA-3D DNA, and total cell lysates were harvested at 48 h after transfection for co-IP
assays. (A) IP was performed with anti-HA, and the precipitates were analyzed by Western blotting (WB) with
anti-FLAG. (B) IP was performed with anti-FLAG, and the precipitates were analyzed by WB with anti-HA. (C)
Uninfected RD cells were transfected with vector or pHA-3D, and cell lysate proteins that were
immunoprecipitated with anti-HA were subjected to WB with anti-UGGT1. The expression of FLAG-UGGT1
and HA-3D in the input lysates is indicated.
https://doi.org/10.1371/journal.ppat.1006375.g002
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Fig 3. UGGT1 facilitates EVA71 replication and propagation. (A) Confocal microscopy results of UGGT1 and 3D expression in
NC or UGGT1 siRNA-treated RD cells that were infected with EVA71 and subjected to immunostaining at 6 h post-infection. Panels 1,
UGGT1 enhancement of viral pathogenicity
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To assess whether the enzymatic activity of UGGT1 is critical for viral replication, we gen-
erated UGGT1 variants lacking monoglucosylation activity (UGGT1(mut)). Previously, it was
shown that UGGT1 enzymatic activity would be abolished after the elimination of monogluco-
sylation activity via mutation [47]. We overexpressed UGGT1 or UGGT1(mut) in infected
cells, and subsequent comparison of viral yields showed no significant difference (S4 Fig), sug-
gesting that UGGT1 enzymatic activity is not critical for viral replication. In light of this, we
propose that UGGT1 may primarily act as a protein bridge to facilitate viral replication.
EVA71-induced pathogenicity decreases in Uggt1 heterozygous
knockout mice
To assess the role of UGGT1 in viral pathogenicity in vivo, we generated Uggt1 knockout mice
from the KOMP-CSD ES cell resource [43]. The Uggt1 gene deletion destroys reglucosylation
activity in cells and is embryonically lethal at day E13 in mice [45]. Homozygous Uggt1 knock-
out mice were embryonically lethal; however, heterozygous mice were viable, fertile, developed
normally, and did not reveal any obvious phenotypic alterations up to adulthood (Fig 4A).
Heterozygous Uggt1 knockout mice expressed only 50–60% of UGGT1 as compared to their
UGGT1 wild-type littermates (Fig 4B). A mouse-adapted EVA71 strain with increased viru-
lence in mice, MP4, was generated after four serial passages of the parental EVA71 strain 4643
in mice [46]. To quantify EVA71 replication rates in wild-type or heterozygous Uggt1 knock-
out mice, the viral load in different mouse tissues on Day 3 after EVA71 infection was assessed.
EVA71 was detected in the brain (Fig 4C) and muscle tissues (Fig 4D), but the viral load in
Uggt1 heterozygous knockout mice was significantly lower than that in wild-type mice. These
results prompted us to investigate the virulence of EVA71 in Uggt1 heterozygous knockout
mice. We challenged 10-day-old wild-type or heterozygous Uggt1 knockout mice with a 105
plaque-forming unit (PFU)/mouse dose of EVA71 strain MP4. Wild-type mice displayed
severe limb paralysis on Day 4 after infection, while heterozygous knockout mice only demon-
strated mild limb paralysis (Fig 4E). Infected wild-type mice began to die on Day 8 after infec-
tion, whereas heterozygous Uggt1 knockout mice began to die on Day 10; however, the 90%
survival rate in infected heterozygous knockout mice was still significantly higher (P< 0.001)
than the 0% survival in wild-type mice (Fig 4F).
To further ascertain if UGGT1 plays a similarly important role in other virus families with
regard to enhancing virulence and pathogenicity, we selected the Japanese Encephalitis Virus
(JEV) from the family Flaviviridae to study the role of UGGT1 upon virus infection. First, we
performed Western blot analysis to confirm the association between UGGT1 and the NS5
polymerase following JEV infection. Immunoprecipitation experiments using JEV-infected or
mock-infected BHK-21 cell extracts were conducted, and the anti-UGGT1 antibody was able
to immunoprecipitate NS5 polymerase only in JEV-infected cell lysate (S5A Fig). To determine
growth efficiency of the virus in mouse brains, an experiment was carried out in suckling mice
by intracranial inoculation with 104 PFU/mouse of the T1P1 JEV strain. After 7 days post-
5, 9, and 13 were stained with anti-UGGT1 and examined using a FITC filter; panels 2, 6, 10, and 14 were stained with anti-3D and
examined with a rhodamine filter; and panels 3, 7, 11, and 15 were subjected to Hoechst 33258 staining and examined with a DAPI
filter. (B) and (C) RD cells were transfected with NC or UGGT1 siRNA for 48 h, and then challenged with EVA71 at an MOI of 10 or
0.1. A plaque assay was performed to measure viral propagation rates at various timepoints post-infection. The left panels show the
knockdown of uggt1 following siRNA treatment. (D) RD cells were transfected with 1, 2, or 4 μg of pFLAG-UGGT1 or pFLAG-vector
for 48 h, and then challenged with EVA71 at an MOI of 10. A plaque assay was performed to measure viral yields at 6 h post-infection.
(E) UGGT1 was overexpressed by respectively transfecting 1, 2, or 4 μg of plasmid pFLAG-UGGT1 to RD cells, and the panels show
the corresponding increase in UGGT1 levels following overexpression, with actin serving as a loading control. ***P < 0.001,
**P < 0.01, and *P < 0.05, as calculated by two-tailed unpaired Student’s t-test.
https://doi.org/10.1371/journal.ppat.1006375.g003
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Fig 4. Viral yield, neurological symptoms, and lethality in UGGT1 heterozygous knockout mice infected
with EVA71. (A) Phenotypes of UGGT1+/+ wild-type (WT) mice and UGGT1+/− heterozygous knockout mice.
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PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006375 May 17, 2017 10 / 27
infection, we collected suckling mice brain tissue, and performed a plaque assay to determine
viral titers. The results indicated that UGGT1 was able to associate with JEV polymerase NS5
and enhance viral growth efficiency in suckling mice tissue (S5B Fig). These results show that
UGGT1 knockdown can reduce EVA71 and JEV virulence and improve disease outcome.
UGGT1 enhances viral positive- and negative-strand RNA synthesis
The EVA71 life cycle comprises entry, viral mRNA translation, viral RNA synthesis, and virus
assembly. To evaluate the biological significance of UGGT1 in EVA71 replication, we exam-
ined the effects of UGGT1 on EVA71 replication efficiency. NC and UGGT1 siRNA knock-
down RD cells were transfected with EVA71-Luc replicon RNA, and cell firefly luciferase
activity (measured in relative light units, RLU) was measured at 6 h post-transfection. In
EVA71-Luc replicon RNA, the viral genome P1 region was replaced with a firefly luciferase
reporter gene, and luciferase expression therefore reflected viral replication. In UGGT1
siRNA-treated cells, EVA71-Luc replicon luciferase activity was reduced to 55% of the activity
in control cells (Fig 5A). This could be due to loss of UGGT1 promotion of either viral mRNA
translation or viral RNA replication. We therefore examined the effect of UGGT1 on EVA71
cap-independent translation first, using dicistronic and monocistronic IRES-mediated transla-
tion assays [49]. In the dicistronic translation assay, the first cistron (Renilla luciferase, RLuc)
involved cap-dependent translation, while the second cistron (Firefly luciferase, FLuc)
required EVA71 IRES-dependent translation. The ratio of FLuc expression to RLuc expression
reflects IRES-mediated translation activity. We transfected RD cells with NC or UGGT1
siRNA, and a dicistronic reporter plasmid was then co-transfected. After 48 h post-transfec-
tion, cell lysates were collected and used to calculate the ratio of FLuc to RLuc. The results
showed that dicistronic IRES activity in NC siRNA-treated cells was not significantly superior
to the activity in UGGT1 siRNA-treated cells (S6 Fig), and monocistronic IRES activity also
showed no significant difference between NC and UGGT1 siRNA-treated cells (Fig 5B). These
results indicate that assisting viral mRNA translation is not the role played by UGGT1 in
EVA71 infection.
As UGGT1 can be co-purified with the 3D polymerase, we speculated that UGGT1 may
facilitate EVA71 replication by enhancing viral RNA synthesis. To ascertain this, we first mon-
itored viral RNA production in NC or UGGT1 siRNA-treated RD cells that were subsequently
infected with EVA71. Intracellular RNA was isolated at different intervals post-infection, and
EVA71 viral RNA was measured using quantitative real-time reverse transcription polymerase
chain reaction (RT-PCR). Results showed that viral RNA production was 33% lower in
UGGT1 siRNA-treated cells, as compared to NC siRNA-transfected cells (Fig 5C). Viral RNA
levels were further investigated in Uggt1 knockdown cells. EVA71 was used to infect cells, and
viral RNA was extracted at various timepoints post-infection. Slot blot analysis, using specific
RNA probes that recognize positive or negative sense EVA71 RNA, was used to monitor viral
RNA synthesis. The results in Fig 5D show that levels of both positive and negative sense
EVA71 RNA were lower in UGGT1 siRNA-treated cells than NC siRNA-treated cells; specifi-
cally, positive-strand RNA levels were reduced by 20% in UGGT1 siRNA-treated cells, while
(B) UGGT1 expression levels in brain tissue homogenates of UGGT1+/+ WT mice and UGGT1
+/− heterozygous knockout mice, as detected by western blotting. (C) and (D) 10-day-old WT or Uggt1
heterozygous knockout mice were injected with 105 PFU/mouse of EVA71 strain MP4, and on Day 3 after
infection, EVA71 virus was extracted from brain and muscle tissues and quantitated. (E) CNS-like hind limb
paralysis and (F) Survival rates in 10-day-old WT and Uggt1 heterozygous knockout mice injected with 105
PFU/mouse of the EVA71 MP4 strain were evaluated, and one-way ANOVA on ranks (Kruskal-Wallis H test)
was used to determine statistical significance. The number (n) of mice in each group is shown.
https://doi.org/10.1371/journal.ppat.1006375.g004
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Fig 5. UGGT1 enhances viral RNA replication. (A) NC or UGGT1 siRNA-treated RD cells were transfected with EVA71-Luc
replicon RNA, and cells were assayed for firefly luciferase signals (FLuc) at 6 h post-transfection. The right panel indicates the
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negative-strand RNA levels were reduced by 54% (Fig 5D). These results suggest that UGGT1
likely acts to enhance viral RNA synthesis during EVA71 infection.
UGGT1 deploys to the cytosol and colocalizes with viral proteins 3D, 3A,
and 3AB in the membrane fraction
UGGT1 is a key quality control factor and protein folding sensor of the ER. To determine the
localization of UGGT1 in cells following EVA71 infection, we used an anti-calnexin (CNX)
antibody to evaluate proteins located in the ER in an immunoprecipitation assay. CNX is a
transmembrane protein on the ER. In the absence of infection, UGGT1 and CNX were shown
to colocalize in the ER (Fig 6A, panels 5 and 21), but some UGGT1 began deploying out of the
ER to colocalize with the 3D viral polymerase upon EVA71 infection (Fig 6A, panels 20 and
22), to the point where little UGGT1 remained in the ER with CNX. UGGT1 and CNX signals
overlapped by more than 75% in mock-infected cells, but this overlap was reduced to less than
55% in EVA71-infected cells (Fig 6B). We further performed subcellular fractionation to sepa-
rate the cytosol and microsome fractions in mock- or EVA71-infected cell extracts. Micro-
somes are vesicle-like artifacts re-formed from pieces of the ER when cells are broken up in the
laboratory, and can be separated from other cellular components by differential centrifugation.
The cellular protein, calnexin, serves as a marker for the ER component in the microsome frac-
tion. UGGT1 was predominantly located within the ER microsome in the mock cell lysates
(Fig 6C, lanes 3 and 5); however, during EVA71 infection, UGGT1 was found to deploy out of
the ER microsome. The proportion of UGGT1 external to the ER rose from 11% to 37% upon
viral infection (Fig 6C, lane 3 and 4).
EVA71 infection induces the rearrangement of intracellular ER membranes into character-
istic vesicles that assemble into viral RCs. According to Fig 1D and 1F, UGGT1 colocalizes at
RCs in association with the 3D viral polymerase; however, the 3D polymerase does not possess
obvious membrane-binding sequences or properties, and therefore it is unclear as to how it
came to be present in RCs. In contrast, viral protein 3A contains hydrophobic domains and
extensively interacts with the cellular membranes that form RCs, and thus can play an impor-
tant role in membrane reorganization through its interactions with host cellular proteins. To
investigate the effect of UGGT1 co-precipitation with the 3D polymerase upon RC formation,
we transfected plasmids expressing viral protein 3A, 3AB, or 3D into cells, and performed the
membrane protein fractionation assay. ER membranes in cells were modified by the expres-
sion of 3A and 3AB. Levels of UGGT1 and 3D polymerase in the membrane protein fraction
of 3A and 3D co-expressing cells were higher than that from cells expressing 3D alone (Fig
7A). This indicates that the presence of viral proteins 3A or 3AB can enhance levels of UGGT1
and the 3D viral polymerase in the membrane protein fraction. To observe the effect of viral
protein 3A upon the enhancement of UGGT1 levels in the membrane protein fraction, we
used only 3A- or 3AB-expressing cells in the fractionation assay. Results showed that expres-
sion of 3A or 3AB enhanced the amount of UGGT1 by 2.1- and 1.8-fold in the membrane
knockdown efficiency of Uggt1. (B) Monocistronic mRNA containing EVA71 IRES and FLuc was transfected to cells pretreated
with NC or UGGT1 siRNA. At 6 h post-transfection, cell lysates were assayed for FLuc activity. Western blotting data indicates
siRNA knockdown efficiency. Experiments were performed in triplicate to obtain the bar graph. (C) NC or UGGT1 siRNA-
treated RD cells were infected with EVA71 at an MOI of 10. Intracellular viral RNA was isolated at 4, 6, 8, 10, 12, and 14 h post-
infection, and quantitated using real-time RT-PCR. The amount of viral RNA at 14 h post-infection in NC siRNA-transfected
cells was taken as 100%, and the relative amount of viral RNA isolated at each timepoint is presented as a percentage of this.
The right panel indicates knockdown efficiency of Uggt1. (D) RD cells were transfected with NC or UGGT1 siRNA for 48 h and
then reseeded. After 24 h, cells were infected with EVA71 at an MOI of 10, and RNA was extracted at 2, 4, 6, 8, and 10 h post-
infection. RNA was loaded onto a nitrocellulose sheet in the slot blot manifold. The right panel demonstrates Uggt1 knockdown
efficiency. ***P < 0.001 and *P < 0.05, as calculated by two-tailed unpaired Student’s t-test.
https://doi.org/10.1371/journal.ppat.1006375.g005
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Fig 6. UGGT1 deploys from the ER lumen to the cytosol during EVA71 infection. (A) Mock-infected or EVA71-infected cells were
fixed and stained with anti-3D, anti-UGGT1, and anti-CNX antibodies at 2, 4, and 6 h post-infection. Use of an anti-3D antibody is shown
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protein fraction (Fig 7B). To evaluate the effect of UGGT1 levels on the amount of 3D poly-
merase in the membrane protein fraction, we co-transfected 3A- or 3AB-expressing plasmids
with pFLAG-3D into NC or UGGT1 siRNA-treated cells, and compared the amount of 3D
polymerase in the membrane protein fractions. Fig 6C shows that the amount of 3D polymer-
ase in Uggt1 knockdown cells decreased to just 90% (3A+3D) or 30% (3AB+3D) of levels in
NC siRNA-treated cells (Fig 7C). We further performed an experiment assessing 3D recruit-
ment to cell membranes with UGGT1 knockdown in the absence of 3A or 3AB. It is well-doc-
umented in poliovirus experimental systems that 3D interacts with 3AB, and therefore it is
important to ascertain whether UGGT1 directly recruits 3D, or if it merely facilitates 3D-3A
interaction. In Fig 7D, the results indicated that the level of 3D recruitment to cell membranes
was the same between NC siRNA- or UGGT1 siRNA-treated cells. These results show that
UGGT1 can indirectly facilitate 3D-3A interactions (Fig 7D), and demonstrate that although
the 3A viral protein can act to enhance levels of UGGT1 and the 3D viral polymerase in mem-
brane protein fractions, the presence of 3D is also partly dependent on UGGT1. To the best of
our understanding, UGGT1 is the first identified host protein that deploys from the ER to the
cytosol following EVA71 infection, and our results indicate that UGGT1 acts to promote 3D
viral polymerase levels in the viral protein 3A-associated membrane fraction, which in turn
may enhance viral replication and increase viral titers.
Discussion
Viral infection typically triggers an arms race between the virus and host cell. For example,
host cells can induce UPR in the ER to restrict viral infection, but viruses can counter this by
manipulating the UPR to facilitate viral propagation. In this study, we showed that expression
of the key UPR factor, UGGT1, not only increases upon viral infection, but UGGT1 interac-
tion with the EVA71 3D polymerase also has positive effects on viral growth and pathogenicity
as well. Immunoprecipitation assays and MALDI-TOF analysis results indicate that the 3D
viral polymerase co-precipitates with UGGT1 during EVA71 infection (Figs 1 and 2), and this
interaction promotes EVA71 replication (Fig 3). Furthermore, heterozygous uggt1 knockout
mice demonstrated lower EVA71 pathogenicity than wild-type mice (Fig 4), and this may be
due to reduction of positive- and negative-strand viral RNA synthesis in the absence of
UGGT1 (Fig 5). We also noted that UGGT1 deploys from the ER to the cytosol upon EVA71
infection (Fig 6), where it enhances 3D polymerase levels in the membrane fraction involved
in RC formation; this process is facilitated by viral protein 3A, which acts to enhance the
amount of UGGT1 in the membrane fraction (Fig 7). Together, these results confirm that
EVA71 can utilize the UPR host defense mechanism and the UPR factor UGGT1 to facilitate
viral RNA synthesis and pathogenicity, via UGGT1 co-precipitation with the 3D viral poly-
merase at RCs.
We used immunoprecipitation assays to identify seven proteins that co-precipitate with the
3D polymerase, and future research could include the evaluation of other 3D polymerase-
in panels 1, 6, 11, and 16, which were examined using a cy5 filter. Use of an anti-UGGT1 antibody is shown in panels 2, 7, 12, and 17,
which were examined using an FITC filter. Use of an anti-CNX antibody is shown in panels 3, 8, 13, and 18, which were examined using
a rhodamine filter. Panels 4, 9, 14, and 19 indicate Hoechst 33258 staining, and were examined with a DAPI filter. Panel 21 displays
enlargement zone 1 from panel 5. Panel 22 displays enlargement zone 2 from panel 20. (B) Percentage of UGGT1 and CNX signal
overlap as calculated with ImageJ JACoP plugins from images shown in (A). The data shown represent the average and standard
deviation of ten randomly selected images. ***P < 0.001, as calculated by two-tailed unpaired Student’s t-test. (C) RD cells were
infected with EVA71, harvested at 6 h post-infection, separated into cytosol and microsome fractions, and subjected to Western blot
analysis using anti-UGGT1 antibody. The same blot was also probed with anti-calnexin, anti-3D, and anti-3A antibodies. The results are
representative of at least three independent and reproducible experiments.
https://doi.org/10.1371/journal.ppat.1006375.g006
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Fig 7. UGGT1 enhances 3D viral polymerase levels in a viral protein 3A-associated membrane fraction. (A) RD cells were co-transfected
with pFLAG-3A and pFLAG-3D; pFLAG-3AB and pFLAG-3D; or pFLAG-3D only, and harvested at 48 h post-transfection. Membrane fractions
were isolated and subjected to Western blot analysis. (B) Cells were transfected with pFLAG-3A, pFLAG-3AB, and pFLAG-vector and harvested
at 48 h post-transfection. Membrane fractions were separated and subjected to Western blot analysis. (C) Cells were transfected with NC or
UGGT1 siRNA for 48 h, and then co-transfected with pFLAG-3A and pFLAG-3D, or pFLAG-3AB and pFLAG-3D. Cells were harvested at 48 h
post-transfection, and the membrane fractions were extracted and subjected to Western blot analysis. Anti-UGGT1, anti-3D and anti-3A
antibodies were used. The same blot was probed with anti-CNX and anti-HSP90 antibodies. (D) Cells were transfected with NC or UGGT1 siRNA
for 48 h, and then co-transfected with pFLAG-3D. Cells were harvested at 48 h post-transfection, and the membrane fractions were extracted and
subjected to Western blot analysis. Anti-3D, anti-UGGT1 and anti-CNX antibodies were used. Results are representative of at least three
independent experiments.
https://doi.org/10.1371/journal.ppat.1006375.g007
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interacting host proteins as to their involvement in EVA71 replication, particularly ILF3
(Table 1). ILF3 acts to facilitate double-stranded RNA-regulated gene expression at the post-
transcriptional level [50,51]. In recent years, investigators have developed an increasing inter-
est in ILF3 and its interaction with select viral proteins [52–54]. It is known that ILF3 interacts
with the 3’ stem-loop structure of dengue RNA and serves as a positive regulator of dengue
virus replication [55]; however, ILF3 is also known to inhibit influenza virus replication during
the early phase of infection via direct interactions with viral nucleoproteins [56]. These find-
ings suggest that ILF3 can play both positive and negative regulatory roles in different types of
viral infections. There is currently no research on the role of ILF3 in the EVA71 life cycle, and
therefore further investigation on the effects of ILF3 in this respect could have significant
import. Incidentally, although other proteins known to associate with viral genome RNA were
also identified in Table 1, including elongation factor 2 and eukaryotic translation initiation
factor 3 [57,58], our results show that RNase A treatment did not reduce the co-precipitation
between UGGT1 and the 3D viral polymerase (Fig 1C), and indicate that viral genomic RNA
does not mediate UGGT1-3D interaction. Further research showed that viral proteins 3C,
3AB, and 3A also co-purify with the 3D-UGGT1 complex, and may act to facilitate UGGT1
and 3D interaction.
Previous studies have found that picornavirus RNA replication occurs on the cytoplasmic
surfaces of double-membrane vesicles originating from the ER, Golgi, and lysosomes in
infected cells [31,59–61]. Poliovirus-induced membrane vesicles have also been linked to intra-
cellular vesicular traffic involving COPII-dependent vesicles [62]. A recent study showed that
poliovirus enriches membranes with phosphatidylinositol-4 phosphate, and promotes RNA
replication through the recruitment of relevant viral and cellular proteins [37]. Our findings
were similar in that UGGT1 also distributes from the ER to the cytosol to co-localize with the
3D viral polymerase, and this may help to facilitate EVA71 RC formation. To our understand-
ing, this is the first study to report on an ER protein deploying to the cytosol to co-localize
with the 3D viral polymerase. However, further research is needed to determine the exact loca-
tion of UGGT1 within the viral RC membrane structure, perhaps by using an electron micro-
scope. This research could also include further examination of the effects of UGGT1 and 3D
polymerase association on the membrane secretory pathway.
In S5 Fig, we found that UGGT1 associated with JEV polymerase NS5 upon viral infection,
and enhanced viral pathogenicity. However, the UGGT1 and NS5 interaction may be direct or
indirect. In future, we will seek to perform additional experiments to detect other cellular or
viral proteins involved in the UGGT1-NS5 complex. This research is expected to provide more
information regarding the role of UGGT1 in flavivirus replication.
Mice have two UGGT genes, Uggt1 and Uggt2 [47], but only the Uggt1 gene product dis-
plays reglucosylation activity, and its deletion halts reglucosylation activity in cells [45]. How-
ever, the product of Uggt2 has no reglucosylation activity, and its function is unknown. When
80% of UGGT2 is replaced with the UGGT1 N-terminal substrate recognition domain, reglu-
cosylation activity can be partly restored in vitro, demonstrating that the remaining 20% of the
UGGT2 C-terminal region can serve as a functional glucosyltransferase [63]. To ascertain
whether UGGT1 activity is required during viral replication, or whether UGGT1 merely acts
as a protein bridge, we generated UGGT1 mutation variants lacking monoglucosylation activ-
ity, and subsequently performed UGGT1 overexpression experiments, with the results shown
in S4 Fig. After comparing viral yields between cells in which UGGT1 or UGGT1(mut) was
overexpressed, we found that there was no significant difference, suggesting that the enzymatic
activity of UGGT1 is not required to enhance viral growth. We therefore propose that UGGT1
may primarily serve as a protein bridge that facilitates viral replication.
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In summary, our results demonstrate that UGGT1 can co-precipitate with the 3D polymer-
ase at EVA71 RCs to increase viral RNA replication. This is the first study to describe the
deployment of an ER protein to the cytosol upon viral infection, and the interesting role of
UGGT1 in EVA71 replication suggests that it may provide insight into the development of
novel anti-EVA71 strategies. Investigators have already designed several small molecular drugs
that target the 3D viral polymerase [64–67], and thus it may be feasible to develop therapies
that target either the interaction between 3D and UGGT1, or between 3D and RCs. Ascertain-
ing the functions of other cellular factors in positive-strand RNA virus replication could fur-
ther facilitate the development of unique antiviral strategies, or perhaps allow the harnessing
of these viral proteins for other applications.
Materials and methods
Ethics statement
All animal experiments were conducted in accordance with the policies and procedures set
forth by the Guide for the Care and Use of Laboratory Animals of the National Institutes of
Health. All procedures were approved by the Institutional Animal Care and Use Committee of
Chang Gung University, Taiwan (IACUC approval number CGU15-017).
Cell cultures
Human embryonal rhabdomyosarcoma (RD; from American Type Culture Collection: CRL-
1620) and human glioblastoma (SF268; provided by Dr. Jim-Tong Horng lab at Chang Gung
University, Taiwan) cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM;
Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS; Gibco), and cul-
tured at 37˚C in a 5% CO2 atmosphere. Hamster kidney fibroblast (BHK-21; from American
Type Culture Collection: CCL-10) cells were maintained in RPMI 1640 Medium (Gibco,
Grand Island, NY) supplemented with 2% fetal bovine serum (FBS; Gibco), and cultured at
37˚C in a 5% CO2 atmosphere. For transfection studies, subconfluent (70%) monolayer cul-
tures were transiently transfected or cotransfected with the respective plasmids, using Lipofec-
tamine 2000 (Invitrogen, Carlsbad, CA). Transfected cultures were incubated for a further 48
h before being used in pull-down or co-immunoprecipitation (Co-IP) assays.
Plasmid construction
The pFLAG-UGGT1 plasmid was constructed by amplifying UGGT1 from RD cell total RNA
by RT-PCR, using a UGGT1 primer (50-ATAAGAATGCGGCCGCGGGCTGCAAGGGAGA
CGCGAG-30) containing a NotI restriction enzyme cutting site, and another primer (50-GCT
CTAGATCATAATTCTTCACGTTTCT-30) containing a XbaI restriction enzyme site. The
derived UGGT1 sequence was then cloned into a p3xFLAG-Myc-CMV vector (Sigma-Aldrich,
Munich, Germany). Plasmid pHA-3D was constructed by amplifying the sequence encoding
the 3D viral polymerase from the EVA71 full-length infectious cDNA clone via PCR, using an
EVA71 primer (50-CGGAATTCCGATGGGTGAGATCCAATGGAT-30) containing a EcoRI
restriction enzyme site and another primer (50-ACCTCGAGATCACAATTCGAGCCAAT
TTC-30) containing a XhoI restriction enzyme site. The derived sequence was then cloned into
a pCMV-HA vector (Clontech, Palo Alto, CA).
A UGGT1 variant in which the amino acid residues critical to monoglucosylation activity,
aa 1452–1457, were deleted (UGGT1(mut)), was generated by two-step overlap PCR mutagen-
esis. Primers (5’-CGAGTAATAACTTCTTTGTGGA-3’) and (5’-ATGAATCATGTTAAGAT
TTGAAAG-3’) were used to generate the 5’ fragment and primers (5’-CTTTCAAATCTTAA
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CATGATTCAT-3’) and (5’- GGAATTCCGGAGACAGATCA-3’) were used to generate the
3’ fragment. Primers designated by asterisks were then used to amplify the overlapping frag-
ments for substitution, via Spe1 and EcoR1 sites, into the UGGT1 expression vector (pFLA-
G-UGGT1) described above. The mutation was confirmed by DNA sequencing, and the
resulting plasmid DNA was designated pFLAG-UGGT1(mut) [47].
Immunoprecipitation and co-IP assays
RD cells were infected with EVA71 (strain 4643/TW/98) at a multiplicity of infection (MOI) of
10 and incubated for 6 h, prior to conducting immunoprecipitation or Co-IP assays. Infected
cells were lysed in a buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM sodium chloride
(NaCl), 1% Triton X-100, and a protease inhibitor cocktail (Roche, Mannheim, Germany).
Cell lysates were precleared with mouse immunoglobulin G (IgG) agarose and incubated with
a mouse anti-3D monoclonal antibody on ice for 2 h, after which 50 μL of protein G-Sepharose
beads were added, and the mixtures were incubated at 4˚C overnight. Proteins bound to the
beads were eluted into a 1× sodium dodecyl sulfate (SDS) running buffer by heating at 95˚C
for 5 min. For RNase A treatment, 100 μL of RNase A in an RNase A working buffer (0.5 U)
was added before any antibodies, and the samples were incubated at 37˚C for 25 min. Total
degradation RNA was extracted using an RNeasy kit (Qiagen, Chatsworth, CA), according to
the manufacturer’s recommendations, and gel analysis was conducted. For the JEV immuno-
precipitation assay, BHK-21 cells were infected with JEV (strain T1P1) and incubated for 24 h,
prior to conducting the immunoprecipitation assay.
MALDI-TOF MS analysis
Pull-down products containing eluted proteins were boiled, subjected to 8–16% sodium dode-
cyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and visualized by silver staining or
Western blotting. Each protein band was excised, destained, reduced, alkylated, and digested
with trypsin. To extract the polypeptides, gel particles were subjected twice to consecutive 20
mM sodium bicarbonate and 5% formic acid in 50% acetonitrile treatments. The supernatants
were combined and lyophilized, and the dried polypeptides were recovered by adding 10 μL of
0.1% formic acid, followed by sonication for 1 min. The recovered polypeptides were further
purified using a ZipTip C18 column (Millipore, Billerica, MA), and eluted with acetonitrile to
a final volume of 3 μL. Protein bands were excised and identified using in-gel trypsin digestion,
then analyzed using a Bruker Ultraflex MALDI-TOF mass spectrometer (Bremen, Germany).
After removing the masses derived from the standards, trypsin, matrix proteins, and keratins,
the monoisotopic mass lists for each protonated peptide were subjected to database searches,
and mass lists were exported to the Biotool 2.0 software package to perform peptide mass fin-
gerprinting, using the Mascot (http://www.matrixscience.com) algorithm scoring to identify
proteins.
Immunofluorescence microscopic analysis
RD cells were seeded on 20-mm coverslips to 60% confluency and infected with EVA71 (strain
4643/TW/98) at an MOI of 10. At various post-infection timepoints, cells were washed with
phosphate-buffered saline (PBS) and fixed with 4% formaldehyde for 30 min at room tempera-
ture (RT). Cells were then washed with PBS and permeabilized using 0.75% Triton X-100 for 5
min at RT, then washed again with PBS and incubated in blocking solution (PBS containing
0.5% bovine serum albumin) for 1 h at RT. Cells were then immunostained with an anti-dou-
ble-strand RNA antibody, J2 (diluted 1:200; Scicons, Szirák, Hungary); an anti-3D antibody,
clone 1 (diluted 1:500; prepared in the lab from recombinant 3D protein); an anti-UGGT1
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antibody, K-16 (diluted 1:200; Santa Cruz Biotechnology, Santa Cruz, CA); and an anti-CNX
(calnexin) antibody, H-70 (diluted 1:400; Santa Cruz Biotechnology) for 2 h at 37˚C. After
washing three times with PBS, cells were incubated with Alexa Fluor 568-conjugated donkey
anti-goat IgG (Invitrogen) and Alexa Fluor 488 goat anti-mouse IgG (Invitrogen) for 1 h at
RT. Cell nuclei were stained using Hoechst 33258 (1:500 dilution) for 20 min, according to
methods previously described [68]. The cells were then observed using a confocal laser-scan-
ning microscope (LSM 510 NLO; Zeiss, Jena, Germany).
Transfection of UGGT1 siRNA
RD cells were cultured in six-well plates (2×105 cells/well) for 24 h and then transfected with
UGGT1 siRNA (UGGT1-HSS183580; Invitrogen), using Lipofectamine 2000 according to the
manufacturer’s protocol (Invitrogen).
Cell viability
The cell viability assay was performed using CellTiter-Glo Luminescent Cell Viability Assay
(Promega). For the viability assays, to quantitate ATP generated by metabolically active cells,
negative control (NC) or UGGT1 siRNA transfected cells were plated in 96-well plates at 5,000
cells/well. Cells were lysed with CellTiter-Glo Luminescent Cell Viability Assay reagent (Pro-
mega), and luminescence was read using the GloMax Explorer System according to the manu-
facturer’s instructions.
Analysis of viral RNA levels
Following transfection with NC or UGGT1 siRNA for 2 days, RD cells were seeded onto
12-well plates and incubated for 24 h. Cells were then plated to six-well plates (6×105 cells/
well) and infected with EVA71 at an MOI of 1. After 60 min absorption at 37˚C, the cells were
washed twice and supplemented with medium, then incubated at 37˚C for the indicated time
periods, after which intracellular RNA was extracted using an RNeasy kit (Qiagen, Chatsworth,
CA). Viral RNA was detected via quantitative real-time RT-PCR with a Roche RT-PCR kit and
a Lightcycler LC480 apparatus. The oligonucleotide primers and the probe for detecting
EVA71 RNA were designed by Verstrepen et al [69]. Each sample was assayed in triplicate,
and experiments were independently performed three times. The obtained data were analyzed
using Roche Lightcycler LC480 system software. EVA71 RNA yields were normalized to that
of actin RNA.
Slot blotting
Slot blot analysis for detecting positive-strand and negative-strand viral RNA was performed
as previously described [70]. Viral RNA was extracted and dissolved in a solution of formalde-
hyde and 20× SSC for 30 min at 60˚C. The reaction was then loaded onto a nitrocellulose
membrane in the slot blot manifold. After washing twice, the nitrocellulose membrane was
removed, air dried, and UV crosslinked. Digoxigenin-labeled RNA probes of 100 ng, specific
for the genome or anti-genome of EVA71, were produced using a DIG Northern starter kit
(Roche). The hybridization and detection procedures were performed according to the manu-
facturer’s protocol.
Enterovirus 71-Luc replicon assays
For EVA71-Luc replicon assays, RD cells were transfected with NC or UGGT1 siRNA. Three
days after transfection, the EVA71-Luc replicon (kindly provided by Dr. Craig E. Cameron)
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was transfected into cells. After 6 h, cell lysates were collected, and luciferase expression levels
were determined with the luciferase reporter assay (Promega, Madison, WI) according to the
manufacturer’s instructions.
Dicistronic or monocistronic expression assay
For the dicistronic expression assay, RD cells were transfected with UGGT1 siRNA, and after
3 days, a dicistronic construct, pRHF-EVA71, was cotransfected with UGGT1 siRNA to RD
cells. After 2 days, cell lysates were prepared in a passive buffer (Promega) and examined for
Renilla luciferase (RLuc) and Firefly luciferase (FLuc) activities with a Lumat LB 9507 biolu-
minometer (EG&G Berthold, Wildbad, Germany), using dual-luciferase reporter assays (Pro-
mega) conducted in accordance with the manufacturer’s instructions.
Image analysis
Pixel colocalization of different color channels in confocal images was analyzed using Image J
software and the ColocalizeRGB and Area Calculator plugins.
Protein detection with western blotting
Cellular membrane fractions were collected using the Mem-PER Plus Membrane Protein
Extraction Kit (ThermoFisher Scientific, San Jose, CA), in accordance with the manufacturer’s
instructions. Approximately 40 μg of membrane proteins were separated with 12% polyacryl-
amide gels for SDS-PAGE, and electroblotted onto polyvinylidene fluoride (PVDF) mem-
branes (BioRad, Richmond, CA). PVDF membranes were blocked for 2 h at RT in 5% milk-
TBST (25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween 20), and then stained with anti-
3D antibody (diluted 1:10,000), anti-3A antibody (diluted 1:1,000), anti-UGGT1 antibody
(diluted 1:500), anti-VP2 antibody, MAB979 (diluted 1:2,000; MILLIPORE), anti-CNX (cal-
nexin) antibody (diluted 1:1,000), and an anti-HSP90 (heat shock protein 90) antibody,
ADI-SPS-771 (diluted 1:1,000; Enzo Life Sciences, Farmingdale, NY) for 2 h at 37˚C. After-
wards, the membranes were washed for four times with TBST, and incubated at RT for 1 h
with a peroxidase-conjugated secondary antibody (diluted 1:1,000), after which Amersham
ECL Prime (GE Healthcare, Waukesha, WI) was used for chemiluminescence detection, and
the signal was recorded on X-ray films.
Subcellular fractionation
RD cells were mock infected or infected with EVA71 at an MOI of 10. The cells were harvested
at 6 h post-infection. EVA71-infected cells were washed with PBS on ice, scraped into PBS,
and collected by centrifugation for 5 min at 1,500 × g. Cell pellets were resuspended in hypo-
tonic solution (42 mM KCl, 10 mM MgCl2, 10 mM HEPES, and pH adjusted to 7.4) and
homogenized using a cell cracker (8.020-mm internal diameter, 8.010-mm bead diameter;
HGM, Heidelberg, Germany). The homogenates were subjected to centrifugation for 10 min
at 7,000 × g, after which mitochondrial-rich pellet was removed. The supernatant was collected
and the concentration adjusted to 1 μg/μL using a hypotonic solution, then centrifuged for 45
min at 55,000 rpm at 4˚C. The resulting supernatant was collected and designated as the cyto-
solic fraction. The pellet was resuspended in lysis buffer (10 mM HEPES, pH 7.9, 1.5 mM
MgCl2, 10 mM KCl, 0.5 mM DTT, 1 mg/mL leupeptin, 2 mg/mL aprotonin, 1 mg/mL pepsta-
tin A, 0.5 mM PMSF, 10 mM β-glycerophosphate, 1 mM sodium vanadate, and 0.1% Triton
X-100) to derive the microsome-rich fraction.
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Virus growth and plaque assay
Following transfection with either NC or UGGT1 siRNA for 2 days, RD and SF268 cells were
seeded to 12-well plates and incubated for 24 h. The cells were then infected with EVA71
(strain 4643/TW/98) or EVD68 (strain CGMH/TW/14) at an MOI of 10 or 0.1. The viruses
were allowed to adsorb for 1 h at 37˚C. At various timepoints post-infection, cell lysates and
supernatants of the cell culture medium were collected to determine viral titers, using plaque
assays. At the final time point, cell lysates were collected to measure UGGT1 expression levels.
For plaque assays, virus stocks were serially diluted in PBS and allowed to adsorb onto conflu-
ent cells for 1 h at 37˚C. The inoculum was then removed, and cells were washed twice with
PBS and then covered with 3 mL of an agar medium. After 4 days of incubation, plaques were
counted, and virus concentration was calculated as PFU/mL.
Generation of UGGT1 knockout mice
The mouse strain used in this study was created from an ES cell clone (KOMP ID: CSD66441,
EPD0550_1_E05 clone) obtained from the Knockout Mouse Project (KOMP) Repository sup-
ported by the US National Center for Research Resources-National Institutes of Health
(NCRR-NIH), and which was generated by the CSD consortium for KOMP (https://www.
komp.org/). The ES cell clone was used to generate chimeric mice. Germline transmitted ani-
mals were bred at the Transgenic Mouse Model Core Facility of the National Core Facility Pro-
gram for Biotechnology (NCFPB), Academia Sinica, Taiwan. Animal care and handling were
approved by the Institutional Animal Care and Use Committee of Chang Gung University.
Infection of virus in mice
Uggt1 heterozygous knockout mice were housed under specific-pathogen-free conditions in
individual ventilated cages. Institutional guidelines for animal care and use were strictly fol-
lowed. Mice were intraperitoneally administered with 105 PFU/mouse of EVA71 strain MP4
[46], and were then monitored daily for pathological signs, and sacrificed at various times
post-inoculation. The severity of central nervous system (CNS) syndromes was scored from 0
to 4 using the following criteria for scoring CNS diseases: 4 = death, 3 = paralysis of both hind
legs, 2 = paralysis of one hind leg, 1 = jerky movement, and 0 = normal movement. In the JEV-
infected suckling mice model, 1-day-old WT or Uggt1 heterozygous knockout mice were
injected with 104 PFU/mouse of JEV strain T1P1, and on Day 7 after infection, JEV was
extracted from brain tissues and quantitated.
Determination of viral titers in infected mice
The tissues and organs of EVA71-infected mice and JEV-infected mice were harvested and
stored at −80˚C, and homogenized in DMEM on ice using a Precellys 24 (Bertin Technologies,
Montigny, France) homogenizer. Viral titers in the supernatants of clarified homogenates
were determined by a plaque assay as described above, and expressed as virus titers (PFU/ml).
Supporting information
S1 Fig. Mass spectrometry analysis results for UGGT1. (A) Mass spectrometry results were
used to query the NCBI human and viral protein databases, and this led to the identification of
UGGT1 as one of the proteins associating with the EVA71 3D viral polymerase. The UGGT1
amino acid sequence is shown here, with matched peptides from the mass spectrometry analy-
sis marked in bold red.
(TIF)
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S2 Fig. Cell proliferation and viability assay on RD cells with siRNA-reduced UGGT1
expression. (A) Western blot depicting the knockdown of UGGT1 with siRNA as indicated.
(B) Proliferation of NC siRNA- or UGGT1 siRNA-transfected cells was analyzed by counting
cell numbers every 24 h. (C) Results of the CellTiter-Glo Luminescent Cell Viability Assay
(Promega) following transfection with the indicated siRNAs. Error bars indicate the standard
deviation (SD) of three replicates.
(TIF)
S3 Fig. UGGT1 promotes EVA71 and EVD68 replication and propagation. (A) and (B)
EVA71 propagation in SF268 cells treated with NC or UGGT1 siRNA for 48 h and then infected
with EVA71 at an MOI of 10 or 0.1. Plaque assays were conducted at the indicated timepoints
after infection to measure viral titers. The left panels provide evidence of Uggt1 knockdown fol-
lowing siRNA treatment. (C) and (D) RD cells were transfected with 1, 2, or 4 μg of pFlag-
UGGT1 or pFlag-vector, then infected 48 h later with EVA71 at an MOI of 10. Plaque assays
were performed to measure viral yields at 4 and 6 h post-infection. (E) and (F) EVD68 propaga-
tion in RD cells treated with NC or UGGT1 siRNA for 48 h and then infected with EVD68 at
an MOI of 10 or 0.1. Viral titers were measured by plaque assays at the indicated time points
post-infection, and the left panels confirm Uggt1 knockdown following siRNA treatment.
P< 0.001, P< 0.01, and P< 0.05, as calculated by two-tailed unpaired Student’s t-test.
(TIF)
S4 Fig. EVA71 viral yield in UGGT1 or UGGT1(mut) overexpressed cells. (A) RD cells were
transfected with 4 μg of pFLAG-vector or pFLAG-UGGT1 or pFLAG-UGGT1(mut) for 48 h,
and then challenged with EVA71 at an MOI of 10. A plaque assay was performed to measure
viral yields at 6 h post-infection. (B) UGGT1 was overexpressed by respectively transfecting
4 μg of plasmid pFLAG-vector or pFLAG-UGGT1 or pFLAG-UGGT1(mut) to RD cells, and
the panels show the corresponding increase in UGGT1 levels following overexpression, with
actin serving as a loading control.
(TIF)
S5 Fig. UGGT1 associates with JEV polymerase NS5 and promotes JEV pathogenicity in
suckling mice. (A) JEV-infected and mock-infected cells were harvested and subjected to
immunoprecipitation assays. Immunoprecipitation assays were performed using an anti-
UGGT1 antibody, and the precipitates were analyzed by Western blotting using an anti-NS5
antibody. (B) 1-day-old WT or Uggt1 heterozygous knockout mice were injected with 104
PFU/mouse of JEV strain T1P1, and on Day 7 after infection, JEV was extracted from brain tis-
sues and quantitated. P < 0.001 as calculated by two-tailed unpaired Student’s t-test.
(TIF)
S6 Fig. EVA71 IRES activity in NC or UGGT1 siRNA-transfected cells. (A) RD cells were
transfected with NC siRNA or UGGT1 siRNA for 48 h, after which the dicistronic construct,
pRHF-EVA71, was transfected. After 48 h, the Renilla luciferase (RLuc) and FLuc activity in
cell lysates was analyzed. Bars in the histogram represent FLuc/RLuc activity percentages.
Experiments were performed in triplicate to derive the bar graph.
(TIF)
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